July 3, 2019 08:19 AM EDT
R&D

Boston Bio­med­ical's lead drug fiz­zles in dif­fi­cult-to-treat pan­cre­at­ic can­cer

Natalie Grover

Reporter

Months af­ter a com­bi­na­tion of Cel­gene’s Abrax­ane and the chemother­a­py gem­c­itabine stum­bled in a piv­otal study in­volv­ing pan­cre­at­ic can­cer pa­tients who had un­der­gone sur­gi­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times